Ascom

Belkins
Ascom is a global solutions provider focused on healthcare ICT and mobile workflow solutions. The vision of Ascom is to close digital information gaps allowing for the best possible decisions – anytime and anywhere.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MEDICAL

RECIPHARM AND MODERNA FINALIZE AGREEMENT TO SUPPORT FORMULATION AND FILL-FINISH A PART OF THE MODERNA COVID-19 VACCINE SUPPLY OUTSIDE OF THE U.S.

Recipharm | January 04, 2021

news image

Moderna, Inc. (NASDAQ:MRNA), biotechnology organization spearheading courier RNA (mRNA) therapeutics and vaccines, and Recipharm (STO: RECI-B), a main contract development and manufacturing organization (CDMO), today reported that they have agreed to help detailing and fill-finish a part of the Moderna COVID-19 Vaccine supply outside of the U.S. The action will be acted in Recipharm's medication item producing office located in France. Subject to regulatory approval of the imm...

Read More

MEDICAL

SOSEI HEPTARES' COVID-19 PROGRAM IDENTIFIES POTENT BROAD SPECTRUM ANTI-VIRAL SMALL MOLECULES FOR FURTHER DEVELOPMENT

Sosei Heptares | November 21, 2020

news image

Sosei Group Corporation ("the Company") (TSE: 4565) announces a progress update for its R&D program focused on the design and development of novel drugs targeting the SARS-CoV-2 coronavirus and to treat COVID-19.The program was initiated in April 2020. To date, the Company has applied its world-leading structure-based drug design (SBDD) capabilities and cutting-edge technologies to precision-design new inhibitors of the SARS-CoV-2 Mpro protease, which plays a crucial role in ...

Read More

MEDTECH

PRECISION COATING ANNOUNCES MERGER WITH N2 BIOMEDICAL TO EXPAND MEDICAL COATINGS PLATFORM

N2 Biomedical | September 20, 2021

news image

Precision Coating, a leading medical coatings service provider to interventional, orthopedic, and advanced surgical markets, is pleased to announce a merger with N2 Biomedical, a Bedford, MA-based company. N2 Biomedical, an Ampersand Capital Partners portfolio company, provides nano-engineered surface treatment and coating services to the medical device industry with its low-temperature Ion Implantation Surface Treatments and Ion Beam Assisted Deposition (IBAD) technologies. ...

Read More

AI

CHARLES RIVER AND VALENCE DISCOVERY DECLARE STRATEGIC PARTNERSHIP TO PROVIDE AI-ENABLED DRUG DESIGN CAPABILITIES TO CLIENTS

Valence Discovery, Charles River | April 08, 2021

news image

Charles River Laboratories International, Inc. and Valence Discovery today reported the arrangement of an essential association to give customers admittance to Valence's computerized reasoning stage for sub-atomic property expectation, generative science, and multiparameter improvement. Expanding on research done by Valence's establishing group at Mila, the world's biggest profound learning research organization, the Valence stage empowers the plan of little atom drug ...

Read More

MEDICAL

Recipharm | January 04, 2021

news image

RECIPHARM AND MODERNA FINALIZE AGREEMENT TO SUPPORT FORMULATION AND FILL-FINISH A PART OF THE MODERNA COVID-19 VACCINE SUPPLY OUTSIDE OF THE U.S.

Moderna, Inc. (NASDAQ:MRNA), biotechnology organization spearheading courier RNA (mRNA) therapeutics and vaccines, and Recipharm (STO: RECI-B), a main contract development and manufacturing organization (CDMO), today reported that they have agreed to help detailing and fill-finish a part of the Moderna COVID-19 Vaccine supply outside of the U.S. The action will be acted in Recipharm's medication item producing office located in France. Subject to regulatory approval of the imm...

Read More

MEDICAL

Sosei Heptares | November 21, 2020

news image

SOSEI HEPTARES' COVID-19 PROGRAM IDENTIFIES POTENT BROAD SPECTRUM ANTI-VIRAL SMALL MOLECULES FOR FURTHER DEVELOPMENT

Sosei Group Corporation ("the Company") (TSE: 4565) announces a progress update for its R&D program focused on the design and development of novel drugs targeting the SARS-CoV-2 coronavirus and to treat COVID-19.The program was initiated in April 2020. To date, the Company has applied its world-leading structure-based drug design (SBDD) capabilities and cutting-edge technologies to precision-design new inhibitors of the SARS-CoV-2 Mpro protease, which plays a crucial role in ...

Read More

MEDTECH

N2 Biomedical | September 20, 2021

news image

PRECISION COATING ANNOUNCES MERGER WITH N2 BIOMEDICAL TO EXPAND MEDICAL COATINGS PLATFORM

Precision Coating, a leading medical coatings service provider to interventional, orthopedic, and advanced surgical markets, is pleased to announce a merger with N2 Biomedical, a Bedford, MA-based company. N2 Biomedical, an Ampersand Capital Partners portfolio company, provides nano-engineered surface treatment and coating services to the medical device industry with its low-temperature Ion Implantation Surface Treatments and Ion Beam Assisted Deposition (IBAD) technologies. ...

Read More

AI

Valence Discovery, Charles River | April 08, 2021

news image

CHARLES RIVER AND VALENCE DISCOVERY DECLARE STRATEGIC PARTNERSHIP TO PROVIDE AI-ENABLED DRUG DESIGN CAPABILITIES TO CLIENTS

Charles River Laboratories International, Inc. and Valence Discovery today reported the arrangement of an essential association to give customers admittance to Valence's computerized reasoning stage for sub-atomic property expectation, generative science, and multiparameter improvement. Expanding on research done by Valence's establishing group at Mila, the world's biggest profound learning research organization, the Valence stage empowers the plan of little atom drug ...

Read More